Skip to main content Accessibility help
  • Print publication year: 2009
  • Online publication date: March 2013

Chapter 41 - Iron imaging in neurodegenerative disorders

from Section 6 - Psychiatric and neurodegenerative diseases



Iron plays an important role in normal neuronal metabolism. Excessive iron is, however, considered to be harmful because of its role in causing oxidative stress. It is well established in the literature that abnormal non-heme iron deposits (in different forms) occur in neurodegenerative disorders, including Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis, and neurodegenerative brain iron accumulation (NBIA). This suggests that oxidative stress resulting from imbalance in iron regulation may contribute to the pathological cascade in these diseases. The metabolism of brain iron and its potential role in causing various neurodegenerative disorders has been discussed in detail in Moos and Morgan [1] and Berg and Youdim.[2] Iron imaging will play an important role in understanding the mechanisms and may be useful for early diagnosis of neurodegenerative disorders. This chapter has two objectives: to present the basics of iron signal detection using magnetic resonance imaging (MRI) and to examine the potential of MRI techniques for imaging abnormal iron deposits in various neurodegenerative disorders.

Iron signal in MRI

The MRI approach utilizes the nuclear magnetic resonance of atomic nuclei and, because of the abundance of protons in the human body (primarily in tissue water), MRI machines use signal from protons for imaging. The signal contrast in MR images mainly originates from differences in the proton density, longitudinal relaxation (T1) and transverse relaxation (T2) of protons in different tissues. Additionally in sequences such as gradient echo sequences where there is no 180° radiofrequency pulse to refocus the dephasing resulting from magnetic field inhomogeneity, the amplitude of the gradient echo carries a 1/T2* weighting where 1/T2* = 1/T2 + 1/T2′ where T2′ is the reversible contribution resulting from local magnetic field inhomogeneity. Since MRI detects changes in electromagnetic signals, changes in local magnetic field inhomogeneities caused by the presence of iron alter the signal contrast in the images. The presence of iron is mainly associated with reduction of T1, T2, and T2* relaxation of protons. There has been some recent work on using additional MRI contrasts such as diffusion tensor imaging (DTI) metrics and rotating frame relaxation constants, longitudinal (T1ρ) and transverse (T2ρ), to measure local iron content.

Moos, T, Morgan, EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 2004; 1012: 14–26.
Berg, D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006; 17: 5–17.
Vymazal, J, Brooks, RA, Baumgarner, C, et al. The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med 1996; 35: 56–61.
Haacke, EM, Cheng, NY, House, MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1–25.
Haacke, EM, Ayaz, M, Khan, A, et al. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging 2007; 26: 256–264.
Duyn, JH, van Gelderen, P, Li, TQ, et al. High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci USA 2007; 104: 11796–11801.
Ogg, RJ, Langston, JW, Haacke, EM, Steen, RG, Taylor, JS. The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging 1999; 17: 1141–1148.
Abduljalil, AM, Schmalbrock, P, Novak, V, Chakeres DW. Enhanced gray and white matter contrast of phase susceptibility-weighted images in ultra-high-field magnetic resonance imaging. J Magn Reson Imaging 2003; 18: 284–290.
Haacke, EM, Xu, Y, Cheng, YC, Reichenbach, JR.Susceptibility weighted imaging (SWI). Magn Reson Med 2004; 52: 612–618.
Sehgal, V, Delproposto, Z, Haacke, EM, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22: 439–450.
Stark, DD, Moseley, ME, Bacon, BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985; 154: 137–142.
Runge, VM, Clanton, JA, Smith, FW, et al. Nuclear magnetic resonance of iron and copper disease states. Am J Roentgenol 1983; 141: 943–948.
Drayer, B, Burger, P, Darwin, R, et al. MRI of brain iron. Am J Roentgenol 1986; 147: 103–110.
Breger, RK, Rimm, AA, Fischer, ME, Papke, RA, Haughton VM. T1 and T2 measurements on a 1.5-T commercial MR imager. Radiology 1989; 171: 273–276.
Ordidge, RJ, Gorell, JM, Deniau, JC, Knight, RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335–341.
Gelman, N, Gorell, JM, Barker, PB, et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999; 210: 759–767.
Bartzokis, G, Beckson, M, Hance, DB, et al. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging 1997; 15: 29–35.
Bartzokis, G, Aravagiri, M, Oldendorf, WH, Mintz, J, Marder SR. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med 1993; 29: 459–464.
Michaeli, S, Oz, G, Sorce, DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson’s disease using novel MRI contrasts. Mov Disord 2007; 22: 334–340.
Jensen, JH, Chandra, R, Ramani, A, et al. Magnetic field correlation imaging. Magn Reson Med 2006; 55: 1350–1361.
Pfefferbaum, A, Adalsteinsson, E, Rohlfing, T, Sullivan, EV. Diffusion tensor imaging of deep gray matter brain structures: effects of age and iron concentration. Neurobiol Aging 2008; Epub ahead of print, PMID 18513834.
Hallgren, B, Sourander, P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41–51.
Aoki, S, Okada, Y, Nishimura, K, et al. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 1989; 172: 381–385.
Xu, X, Wang, Q, Zhang, M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 2008; 40: 35–42.
Berg, D, Hochstrasser, H.Iron metabolism in parkinsonian syndromes. Mov Disord 2006; 21: 1299–1310.
Dexter, DT, Wells, FR, Agid, F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987; 2: 1219–1220.
Sofic, E, Riederer, P, Heinsen, H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199–205.
Drayer, BP, Olanow, W, Burger, P, et al. Parkinson-plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986; 159: 493–498.
Vymazal, J, Righini, A, Brooks, RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211: 489–495.
Bartzokis, G, Tishler, TA, Shin, IS, Lu, PH, Cummings, JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 2004; 1012: 224–236.
Martin, WR, Wieler, M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70: 1411–1417.
Hayflick, SJ, Westaway, SK, Levinson, B, et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med 2003; 348: 33–40.
Hayflick, SJ, Hartman, M, Coryell, J, Gitschier, J, Rowley, H.Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230–1233.
Vinod Desai, S, Bindu, PS, Ravishankar, S, Jayakumar, PN, Pal, PK.Relaxation and susceptibility MRI characteristics in Hallervorden–Spatz syndrome. J Magn Reson Imaging 2007; 25: 715–720.
Whitnall, M, Richardson, DR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 2006; 13: 186–197.
Bartzokis, G, Lu, PH, Tishler, TA, et al. Myelin breakdown and iron changes in Huntington’s disease: pathogenesis and treatment implications. Neurochem Res 2007; 32: 1655–1664.
Gil, JM, Rego, AC. Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 2008; 27: 2803–2820.
Bartzokis, G, Cummings, J, Perlman, S, Hance, DB, Mintz, J.Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999; 56: 569–574.
Vymazal, J, Klempir, J, Jech, R, et al. MR relaxometry in Huntington’s disease: correlation between imaging, genetic and clinical parameters. J Neurol Sci 2007; 263: 20–25.
Mantyh, PW, Ghilardi, JR, Rogers, S, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993; 61: 1171–1174.
Smith, MA, Harris, PL, Sayre, LM, Perry, G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866–9868.
Bartzokis, G, Sultzer, D, Cummings, J, et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 2000; 57: 47–53.
House, MJ, St. Pierre, TG, Foster, JK, Martins, RN, Clarnette, R.Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNR Am J Neuroradiol 2006; 27: 430–439.
House, MJ, St. Pierre, TG, Kowdley, KV, et al. Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer’s disease patients. Magn Reson Med 2007; 57: 172–180.
Jack, CR, Jr., Garwood, M, Wengenack, TM, et al. In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 2004; 52: 1263–12671.
Vanhoutte, G, Dewachter, I, Borghgraef, P, van Leuven, F, van der Linden, A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer’s disease. Magn Reson Med 2005; 53: 607–613.
Wadghiri, YZ, Sigurdsson, EM, Sadowski, M, et al. Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50: 293–302.
El Tayara Nel T, Volk A, Dhenain, M, Delatour, B.Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. Magn Reson Med 2007; 58: 179–184.
Vernooij, MW, van der Lugt, A, Ikram, MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008; 70: 1208–1214.
Schneider, JA.Brain microbleeds and cognitive function. Stroke 2007; 38: 1730–1731.
O’Rourke, MF. Brain microbleeds, amyloid plaques, intellectual deterioration, and arterial stiffness. Hypertension 2008; 51: e20; author reply e21.
Cordonnier, C, van der Flier, WM, Sluimer, JD, Leys, D, Barkhof, F, Scheltens, P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356–1360.
Drayer, B, Burger, P, Hurwitz, B, Dawson, D, Cain, J. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?Am J Roentgenol 1987; 149: 357–363.
Bakshi, R, Shaikh, ZA, Janardhan, V.MRI T2 shortening (“black T2”) in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000; 11: 15–21.
Zhang, Y, Zabad, RK, Wei, X, et al. Deep grey matter “black T2” on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult Scler 2007; 13: 880–883.
Bermel, RA, Puli, SR, Rudick, RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005; 62: 1371–1376.
Bakshi, R, Dmochowski, J, Shaikh, ZA, Jacobs, L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001; 185: 19–26.
Ge, Y, Jensen, JH, Lu, H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007; 28: 1639–1644.
Brass, SD, Benedict, RH, Weinstock-Guttman, B, Munschauer, F, Bakshi, R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 2006; 12: 437–444.